PSMA scan for better prostate cancer treatment with HIFU
Part of Cancer, Kidney & urinary clinical trials.
This study uses a special PSMA PET scan to improve how prostate cancer is seen and treated with HIFU (a focused ultrasound that destroys cancer cells). If it works, the scan may help guide treatment more precisely and reduce harm to healthy tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have prostate cancer and be 70 years of age or older.
- Your doctor expects you to live more than 5 more years, so the treatment is worth doing.
- The cancer must be at an early stage (T1c or T2a) with a PSA level under 20 and a low or intermediate Gleason grade group (ISUP 2 or less).
- An MRI must show a single suspicious spot (PIRADS 3, 4, or 5) and your prostate must be smaller than 150 ml (about the size of a large orange).
- You must not have severe kidney disease (eGFR 60 or below) or liver problems, and you must be able to have an MRI (no metal implants).
- You must be willing to sign a consent form and be covered by a social security plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.
This trial tests whether a special PET scan (called PSMA, which pictures prostate cancer cells) can help doctors better find any remaining or spread of prostate cancer when your PSA level is rising again. It's for people who are planning radiation therapy, and the goal is to see if the scan changes the treatment plan.
This trial uses a special PET/MRI scan to check if prostate cancer has come back after high-intensity focused ultrasound (HIFU) treatment. It aims to find any remaining cancer early so doctors can plan next steps.
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
This Phase 3 study checks whether a PSMA PET/CT scan (using a special tracer) can help doctors make better decisions for people with prostate cancer after treatment, based on PSA blood test changes. It may help identify whether cancer has spread or how to plan next steps.
This study tests whether a special PET scan (PSMA PET) can better detect prostate cancer in men whose MRI results are unclear. If it works, it may help avoid unnecessary biopsies or find cancer sooner.
Hear when a new Prostate Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.